STOCK TITAN

ZOETIS INC. - ZTS STOCK NEWS

Welcome to our dedicated page for ZOETIS news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on ZOETIS stock.

Zoetis Inc. (symbol: ZTS) is a leading American pharmaceutical company and the world's largest producer of medicines and vaccinations for pets and livestock. Originally a subsidiary of Pfizer, Zoetis became an independent company following Pfizer’s spinoff of its 83% interest. Zoetis specializes in a wide range of products including anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals.

The company's revenue is split between production animals (cattle, pigs, poultry, etc.), which contribute approximately 35%, and companion animals (dogs, horses, cats), which account for nearly 65%. In the U.S., Zoetis' business is predominantly focused on companion animals, while its international operations have a slight inclination towards production animals. As an industry leader, Zoetis holds the largest market share and continues to lead in innovation and product development for animal health.

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity. Financially, Zoetis remains robust with consistent revenue growth and strategic partnerships to expand its market reach. Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

Stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. to make informed investment decisions.

Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) has declared a fourth quarter 2021 dividend of $0.25 per share, payable on December 1, 2021, to stockholders on record as of October 29, 2021. As a leader in animal health, Zoetis generated revenue of $6.7 billion in 2020, supported by a workforce of approximately 11,300 employees. The company focuses on advancing animal care through innovations in medicines, vaccines, and diagnostics globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
dividends
-
Rhea-AI Summary

Zoetis Inc (NYSE:ZTS) will host a webcast on November 4, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and address questions from analysts. Interested parties can access the live webcast on the Zoetis investor relations website. A replay will be available after the event. Zoetis generated $6.7 billion in revenue in 2020 and has a strong portfolio of animal health products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
conferences earnings
-
Rhea-AI Summary

Zoetis has been recognized for the eighth consecutive year as one of Seramount’s 100 Best Companies, underscoring its commitment to family-friendly benefits and flexible work arrangements. Notably, Kristy Earley-Murray was named Working Mother of the Year, and Chip Dorsey is the first recipient of Working Father of the Year. These honors highlight Zoetis' dedication to supporting working parents, particularly during the ongoing challenges posed by the COVID-19 pandemic, as stated by Executive VP Roxanne Lagano.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
Rhea-AI Summary

Zoetis (NYSE:ZTS) will participate in the Jefferies Virtual Pet Care Summit on September 16, 2021. Executive Vice President Glenn David will represent the company during the presentation at 11:00 a.m. ET. Investors can access a live audio webcast of the presentation at investor.zoetis.com/events-presentations. A replay will be available afterward. Zoetis, a leader in animal health, generated $6.7 billion in revenue in 2020, employs approximately 11,300 individuals, and operates in over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
conferences
-
Rhea-AI Summary

Zoetis reported a strong Q2 2021, with revenue of $1.9 billion, a 26% increase year-over-year, and net income up 36% to $512 million. Adjusted net income rose 33% to $566 million ($1.19 per share). U.S. revenue grew 22%, driven by a 34% rise in companion animal products, while international sales surged 31%. The company raised its full-year guidance, projecting revenue between $7.625 billion and $7.700 billion, reflecting strong growth drivers despite expectations of modest growth in H2 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
none
-
Rhea-AI Summary

Zoetis (NYSE: ZTS) announced an agreement to acquire Jurox, an animal health company known for its veterinary medicines for companion animals and livestock. This acquisition will enhance Zoetis' global expansion efforts, particularly in Australia, its fifth-largest market with $207 million in revenue in 2020. Jurox brings a valuable product portfolio, including Alfaxan®, and over 150 products aimed at animal health. The transaction, awaiting regulatory approval, is expected to close in the first half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
Rhea-AI Summary

Zoetis is donating over 11,000 doses of its experimental COVID-19 vaccine to protect more than 100 mammalian species in nearly 70 zoos across 27 states. Authorized for use by the USDA, the vaccine aims to combat COVID-19 risks in at-risk animals, such as tigers and gorillas. The first vaccinations began at Oakland Zoo on June 30, 2021. The vaccine utilizes a unique formulation for animals, developed from Zoetis' extensive experience with other coronaviruses. This initiative reflects Zoetis' commitment to animal health and sustainability, as they monitor emerging infectious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
covid-19
-
Rhea-AI Summary

Zoetis Inc (NYSE:ZTS) will host a webcast and conference call on Aug. 5, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results. CEO Kristin Peck and CFO Wetteny Joseph will present the results and answer questions from analysts. Investors can access the live webcast on the Zoetis investor site. The company, a leader in animal health, achieved $6.7 billion in revenue in 2020 and operates in over 100 countries, focusing on medicines, vaccines, and services for animal care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
conferences earnings
-
Rhea-AI Summary

Zoetis' A.L.P.H.A. initiative has significantly improved livestock health in Sub-Saharan Africa by administering 1.7 billion doses of vaccines and medicines, alongside over 650,000 diagnostic tests. Established in 2017 with a $14 million grant from the Gates Foundation, the program has trained over 13,200 individuals and established 10 serology labs. Zoetis submitted 85 veterinary products for approval and delivered 35 to the market, enhancing access to animal health services. The initiative aims to promote sustainable livestock practices, improve farmers' livelihoods, and contribute to economic development amidst challenges like COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.06%
Tags
none

FAQ

What is the current stock price of ZOETIS (ZTS)?

The current stock price of ZOETIS (ZTS) is $176.42 as of November 18, 2024.

What is the market cap of ZOETIS (ZTS)?

The market cap of ZOETIS (ZTS) is approximately 79.5B.

What does Zoetis Inc. specialize in?

Zoetis Inc. specializes in medicines and vaccinations for pets and livestock, including anti-infectives, vaccines, parasiticides, diagnostics, and other health products.

Is Zoetis Inc. still part of Pfizer?

No, Zoetis Inc. became an independent company after Pfizer spun off its 83% interest.

What percentage of Zoetis' revenue comes from companion animals?

Nearly 65% of Zoetis' revenue comes from companion animal products such as those for dogs, horses, and cats.

Which segment contributes more to Zoetis' U.S. business?

Zoetis' U.S. business is heavily skewed toward companion animals.

How does Zoetis' international business differ from its U.S. business?

Internationally, Zoetis' business is slightly skewed towards production animals, unlike its U.S. business, which focuses more on companion animals.

What recent achievements has Zoetis Inc. accomplished?

Recent achievements include the launch of new vaccines and diagnostic tools aimed at improving animal health and productivity.

What are Zoetis' current projects?

Current projects include advancing their R&D pipeline to develop next-generation animal health solutions and expanding their global footprint through acquisitions and collaborations.

What is Zoetis' market position in the industry?

Zoetis holds the largest market share in the animal health industry.

Does Zoetis have any strategic partnerships?

Yes, Zoetis has strategic partnerships to expand its market reach and foster innovation.

Where can I find the latest updates on Zoetis Inc.?

You can stay updated with the latest performance metrics, developments, and events related to Zoetis Inc. on StockTitan and other financial news platforms.

ZOETIS INC.

NYSE:ZTS

ZTS Rankings

ZTS Stock Data

79.51B
451.17M
0.2%
96.44%
0.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
PARSIPPANY